NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) has reported encouraging clinical and regulatory developments that could reshape the treatment landscape for recurrent brain cancer. The company's lead candidate, NEO100, met its primary endpoint in a Phase 2a study, demonstrating a six-month progression-free survival (PFS-6) rate of 48.9% using RANO 2.0 criteria and Kaplan-Meier estimation, compared to a pre-specified 20% benchmark (p=0.0047). Median overall survival (OS) reached 26.09 months, with no major toxicities observed. These results, announced in conjunction with Stonegate Capital Partners' updated coverage, underscore the potential of NEO100 as a viable therapeutic option in a disease area with limited effective treatments.
The survival data are particularly compelling, given that current salvage therapies for recurrent brain cancer typically yield only 6–9 months of benefit. The positive readout moves NEO100 closer to a registrational program, with the company planning to request a Type B FDA meeting to align on trial design and endpoints. This regulatory clarity is crucial, as it could accelerate the path to approval and address a significant unmet medical need.
Beyond NEO100, NeOnc has made strides with its second clinical candidate, NEO212. The company received Phase 2 CMC clearance and FDA feedback indicating a potential accelerated approval pathway. This diversification reduces reliance on a single asset and enhances the company's long-term optionality. NEO100 is also being explored in meningioma and pediatric brain tumors, broadening its potential indications.
Financially, the company's focus remains on advancing its pipeline, with R&D expenses increasing to $2.6 million in the second quarter of 2026, up from $0.7 million year-over-year. While funding is a consideration as development activities expand, the recent clinical and regulatory milestones strengthen the investment thesis.
For more details, refer to the full announcement from Stonegate Capital Partners, which includes additional insights and downloadable resources. The progress made by NeOnc highlights the potential for innovative therapies to improve outcomes in brain cancer, a field that has seen limited advancements in recent years.
